Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological effects of LEO 43204 in actinic keratosis
NCT02600598Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2016
- Primary completion
- Dec 2016
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ingenol disoxate in actinic keratosis (AK) (2 arms), sponsored by LEO Pharma. Primary endpoint: Number of CD3+ T lymphocytes assessed by immunohistochemistry at 56 days. Started Jul 2016; status: completed.
02
Drugs
ingenol disoxate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02600598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02600598.